Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers.

Inagaki Y, Hunt T, Arana B, Gosho M, Morgan R.

J Clin Pharmacol. 2011 Sep;51(9):1302-9. doi: 10.1177/0091270010379811. Epub 2011 Jan 12.

PMID:
21228405
2.

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.

Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, Hunt TL, Morgan RE.

Curr Med Res Opin. 2012 Feb;28(2):187-94. doi: 10.1185/03007995.2011.648264. Epub 2012 Jan 9.

PMID:
22149769
3.

Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.

Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.

Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.

PMID:
20171423
4.

Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers.

Jung JA, Noh YH, Jin S, Kim MJ, Kim YH, Jung JA, Lim HS, Bae KS.

Clin Ther. 2012 Apr;34(4):958-65. doi: 10.1016/j.clinthera.2012.01.026. Epub 2012 Mar 10.

PMID:
22410289
5.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021
7.

Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Almeida L, Falcão A, Vaz-da-Silva M, Nunes T, Santos AT, Rocha JF, Neta C, Macedo T, Fontes-Ribeiro C, Soares-da-Silva P.

Eur J Clin Pharmacol. 2008 Oct;64(10):961-6. doi: 10.1007/s00228-008-0534-2. Epub 2008 Aug 6.

PMID:
18679669
8.

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.

Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.

J Clin Pharmacol. 2009 Oct;49(10):1157-67. doi: 10.1177/0091270009341653.

PMID:
19783710
9.

Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.

Kirby LC, Johnson BM, Adams LM, Eberwein DJ, Zhang K, Murray SC, Lates CD, Blum RA, Morris SR.

J Clin Pharmacol. 2010 May;50(5):566-75. doi: 10.1177/0091270009346965. Epub 2010 Mar 10.

PMID:
20220045
10.
11.

Absence of a pharmacokinetic interaction between etanercept and warfarin.

Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.

J Clin Pharmacol. 2004 May;44(5):543-50.

PMID:
15102876
12.

Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.

Jindal D, Tandon M, Sharma S, Pillai KK.

Eur J Clin Pharmacol. 2005 Oct;61(9):621-5. Epub 2005 Oct 19.

PMID:
16133549
13.

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.

Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ.

Diabetes Obes Metab. 2013 Apr;15(4):316-23. doi: 10.1111/dom.12028. Epub 2012 Nov 22.

PMID:
23094794
14.

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.

Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E.

J Clin Pharmacol. 2009 Dec;49(12):1456-66. doi: 10.1177/0091270009344335. Epub 2009 Sep 30.

PMID:
19793910
15.

Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.

Adv Ther. 2008 Nov;25(11):1175-90. doi: 10.1007/s12325-008-0116-9.

PMID:
18989636
16.

Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.

Stockis A, van Lier JJ, Cawello W, Kumke T, Eckhardt K.

Epilepsia. 2013 Jul;54(7):1161-6. doi: 10.1111/epi.12192. Epub 2013 Apr 24.

17.

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D.

Curr Med Res Opin. 2007 May;23(5):1131-8.

PMID:
17519080
18.

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.

Groenendaal-van de Meent D, den Adel M, Rijnders S, Krebs-Brown A, Kerbusch V, Golor G, Schaddelee M.

Clin Ther. 2016 Apr;38(4):918-28. doi: 10.1016/j.clinthera.2016.02.010. Epub 2016 Mar 4.

PMID:
26947173
19.

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.

Am J Ther. 2009 May-Jun;16(3):215-23. doi: 10.1097/MJT.0b013e31818f9c68.

PMID:
19454860
20.

No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin.

Schall R, Müller FO, Hundt HK, Ritter W, Duursema L, Groenewoud G, Middle MV.

J Clin Pharmacol. 1995 Mar;35(3):306-13.

PMID:
7608323

Supplemental Content

Support Center